Addressing Viral Pandemics Such as COVID-19

The Carterra LSA can screen and characterize thousands of samples with the speed and throughput needed to easily meet the limited timelines of rapidly evolving threats such as COVID-19. The LSA’s patented microfluidics enable it to characterize epitope and affinity using sample quantities far below other technologies. Speed in conjunction with high resolution is vital towards making informed decisions during viral pandemics.

• Understand mechanism of action (MOA) for therapeutic cocktails
• Characterize kinetics, epitope, blocking, and specificity on a single platform
• Leverage critical antibody-antigen insights to evaluate preclinical/clinical outcomes
• Fully characterize thousands of samples in a week using ultra-low sample quantities

Read the White Paper